Open an account

Allarity Therapeutics

ALLR · NASDAQ

$0.8758+$0.0028 (+0.32%)TodayMarket closed ·
Prev close $0.873

About ALLR

Allarity Therapeutics, Inc. engages in the development of drugs for personalized treatment of cancer guided by its proprietary Drug Response Predictor (DRP) technology. The company is headquartered in Boston, Massachusetts and currently employs 7 full-time employees. The company went IPO on 2021-12-21. The company is focused on development of stenoparib, a PARP/tankyrase inhibitor for advanced ovarian cancer patients, using its DRP technology to develop a companion diagnostic that can be used to select those patients expected to derive clinical benefit from stenoparib. Its therapeutic candidate, stenoparib, is a dual inhibitor of the key DNA damage repair enzyme PARP, as well as Tankyrases, critical enzymes involved in the WNT signaling pathway commonly activated in many cancers. Inhibition of key DNA damage repair enzymes, such as PARP, has clinically demonstrated to be therapeutically beneficial in the treatment of cancers (ovarian cancers). The DRP method builds on the comparison of sensitive vs. resistant human cancer cell lines, including transcriptomic information from cell lines, combined with clinical tumor biology filters and prior clinical trial outcomes.

Employees
7
Headquarters
Boston, Massachusetts
Listed
Dec 21, 2021
Sector
Health Care
Industry
Biotechnology
Website
allarity.com

ALLR key statistics

Market cap
13.93M
Price-earnings ratio
0.00
Dividend yield
—
Average volume
126.80K
Volume
108.54K
Open price
$0.88
High today
$0.9075
Low today
$0.8701
52 Week high
$1.84
52 Week low
$0.7687

Allarity Therapeutics (ALLR) at a glance

Allarity Therapeutics (ALLR) last traded at $0.8758, with a market cap of 13.93M and a price-to-earnings ratio of 0.00.

Today the stock has traded between $0.8701 and $0.9075. The current price is 0.7% above the day's low and 3.5% below its high.

Volume so far is 108.54K shares, in line with the average of 126.80K shares a day.

Over the past year Allarity Therapeutics has ranged from $0.7687 to $1.84, and now sits 10% of the way up that range.

Allarity Therapeutics met or beat analyst EPS estimates in 7 of the last 8 quarters. In Q2 FY26 it reported -$0.21 per share against an estimate of -$0.255.

The average analyst price target is $11.22, 1181.1% above the current price, from 1 recent ratings.

Analyst ratings

Latest rating from each analyst over the past 12 months

100%of 1 analyst rating say Buy
  • Buy100.0%
  • Hold0.0%
  • Sell0.0%
Price target · 3 analystsAvg $11.22
Low
$11.11
Now
$0.8758
High
$11.55

ALLR earnings

Earnings per share, reported against the analyst estimate

Beat the estimate in 7 of the last 8 quarters, by 24.4% on average.

  1. Q1 FY24: reported -$664.20 per share against an estimate of -$53.86
  2. Q2 FY24: reported -$3.30 per share against an estimate of -$8.78
  3. Q3 FY24: reported -$7.71 per share against an estimate of -$8.69
  4. Q2 FY25: reported -$0.15 per share against an estimate of -$0.2142
  5. Q3 FY25: reported -$0.19 per share against an estimate of -$0.2346
  6. Q4 FY25: reported -$0.211 per share against an estimate of -$0.2244
  7. Q1 FY26: reported -$0.17 per share against an estimate of -$0.2244
  8. Q2 FY26: reported -$0.21 per share against an estimate of -$0.255

ALLR news

  • 12 Health Care Stocks Moving In Wednesday's Pre-Market Session

  • Avi Kapoor

    Crude Oil Down 2%; US Durable Goods Orders Decline In July

  • Avi Kapoor

    US Stocks Mixed; American Woodmark Posts Downbeat Sales

  • Press releasePRNewswire

    ALLR Shareholders are Encouraged to Join Allarity Therapeutics, Inc. Securities Fraud Investigation with the Schall Law Firm

  • Press releasePRNewswire

    ALLR Shareholders are Encouraged to Join Allarity Therapeutics, Inc. Securities Fraud Investigation with the Schall Law Firm

  • Rishabh Mishra

    US Stocks Likely To Open Mixed After Disappointing Q1 Performance: 'April Does Better After A Weak Q1,' Says Expert

  • Avi Kapoor

    XPeng, Ultralife And 3 Stocks To Watch Heading Into Tuesday

  • Press releasePRNewswire

    ALLR Shareholders are Encouraged to Join Allarity Therapeutics, Inc. Securities Fraud Investigation with the Schall Law Firm

Similar companies

Companies in the same industry as Allarity Therapeutics

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.